Abstract
In conclusion, it appears that tocainide will be an extremely important new antiarrhythmic agent in the armamentarium of the clinical cardiologist (Table V). Its similarity to lidocaine and the predictability of its efficacy in patients responsive to lidocaine is an important note. Its lack of interaction with beta blockers and digoxin is also a promising feature. While tocainide has proven to be effective in the prophylaxis and treatment of patients with both refractory and chronic ventricular arrhythmias, its efficacy is in the approximate range of other class I agents, such as quinidine, procainamide, and disopyramide. Its side effect profile appears to be similar in percentage to the adverse effects of quinidine, but often these side effects are milder, better tolerated, and respond to dosage alteration. Thus, tocainide will undoubtedly prove to be a useful new antiarrhythmic agent, particularly when compared to the currently available antiarrhythmic agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
